Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study

Hao,Guangtao; Bai,Shaobo; Liang,Haixia; Liang,Yuguang; Qu,Hengyan; Gao,Hongzhi; Li,Yuanyuan; Zheng,Zhuanjie; Wang,Xiaofang; Liu,Zeyuan

doi:10.3892/etm.2013.908

Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study

Authors:
- Guangtao Hao
- Shaobo Bai
- Haixia Liang
- Yuguang Liang
- Hengyan Qu
- Hongzhi Gao
- Yuanyuan Li
- Zhuanjie Zheng
- Xiaofang Wang
- Zeyuan Liu
View Affiliations

Affiliations: Department of Pharmacology, Affiliated Hospital of the Academy of Military Medical Sciences, Beijing 100071, P.R. China, Pharmacy Department, The Fifth Hospital of PLA, Yinchuan 750004, P.R. China, Department of Pharmacy, Beijing Anding Hospital, Capital Medical University, Beijing 100088, P.R. China
Published online on: January 18, 2013 https://doi.org/10.3892/etm.2013.908
Pages: 932-936

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A rapid, sensitive and specific HPLC-MS/MS method was developed and validated for the quantification of potassium oxonate (Oxo) in human plasma using [13C2,15N3]‑Oxo as an internal standard (IS). The target substance was separated from human plasma using the solid-phase extraction method. Chromatography separation was performed on a Waters:Atlantis dC18 column (150x4.6 mm, 5.0 µm) with a mobile phase consisting of H2O with 0.1% formic acid in acetonitrile (90:10, v/v). The mass spectrometer works with electrospray ionization and multiple reaction monitoring in its negative ion mode, using target ions at [M-H]- m/z 111.9 for Oxo and [M-H]- m/z 117.0 for the IS. The mean standard curve was linear (r=0.9991) over the concentration range of 2.0-200.0 ng/ml and had good back-calculated accuracy and precision. The intra- and inter-day precision were <6.33% and the accuracy was >99.38%. The extraction recovery was >60.26%. The lower limit of quantification achieved with this method was 2.0 ng/ml. This assay method was demonstrated to be accurate, sensitive and simple and was successfully applied to a pharmacokinetic study following single oral administration of a 40-mg S-1 capsule in 12 tumor patients.

View Figures

View References

1.	Kubota T: The role of S-1 in the treatment of gastric cancer. Br J Cancer. 98:1301–1304. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma ortho-topically implanted into nude rats. Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
3.	Blum M, Suzuki A and Ajani JA: A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol. 6:715–726. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Shimoyama S, Kiyokawa T, Nishida M and Seto Y: S-1 monotherapy achieved twenty-month survival for peritoneal lavage cytology-positive gastric cancer patient undergoing noncurative resection. Gan To Kagaku Ryoho. 9:1411–1414. 2012.(In Japanese).
5.	Yamashita T, Arai K, Terashima T, et al: A case report of S-1 monotherapy for advanced hepatocellular carcinoma. Gan To Kagaku Ryoho. 9:1435–1437. 2012.(In Japanese).
6.	Iwasa S, Yamada Y, Kato K, Goto A, Honma Y, Hamaguchi T and Shimada Y: Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. Anticancer Res. 9:4157–4161. 2012.PubMed/NCBI
7.	Kogashiwa Y, Nagafuji H and Kohno N: Feasibility of concurrent chemoradiotherapy with S-1 administered on alternate days for elderly patients with head and neck cancer. Anticancer Res. 32:4035–4040. 2012.PubMed/NCBI
8.	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Shirasaka T, Shimamoto Y and Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 53:4004–4009. 1993.PubMed/NCBI
10.	American Association for Cancer Research: 86th Annual Meeting: Proceedings; 36. American Association for Cancer Research; Toronto: pp. 4061995
11.	Kitamura R, Satoh T, Maeda M and Tsuji A: Enzyme immunoassay of potassium oxonate using specific antibody isolated by immunosorbent gel. Yakugaku Zasshi. 114:171–175. 1994.(In Japanese).
12.	Matsushima E and Yoshida K, Kitamura R and Yoshida K: Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl. 691:95–104. 1997.
13.	Schwaninger AE, Meyer MR, Huestis MA and Maurer HH: Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. J Mass Spectrom. 46:603–614. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Liu K, Zhong D, Zou H and Chen X: Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 52:550–556. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Star-Weinstock M, Williamson BL, Dey S, Pillai S and Purkayastha S: LC-ESI-MS/MS Analysis of Testosterone at Sub-Picogram Levels Using a Novel Derivatization Reagent. Anal Chem. 84:9310–9317. 2012.PubMed/NCBI
16.	Giorgianni F, Mileo V, Desiderio DM, Catinella S and Beranova-Giorgianni S: Characterization of the phosphoproteome in human bronchoalveolar lavage fluid. Int J Proteomics. 2012:4602612012. View Article : Google Scholar : PubMed/NCBI
17.	de Mateo S, Estanyol JM and Oliva R: Methods for the analysis of the sperm proteome. Methods Mol Biol. 927:411–422. 2013.
18.	Hirata K, Horikoshi N, Aiba K, et al: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 5:2000–2005. 1999.PubMed/NCBI
19.	Peters GJ, Noordhuis P, Van Kuilenburg AB, et al: Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol. 52:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Mende B, Krauss J, Thyssen D, et al: Pharmacokinetic study of S-1. Int J Clin Pharmacol Ther. 47:65–67. 2009. View Article : Google Scholar